Nextage Therapeutics Ltd (TLV:NXTG)
Israel · Delayed Price · Currency is ILS · Price in ILA 59.00
+8.10 (15.91%)
At close: Jun 12, 2026
Nextage Therapeutics Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 0.24 | 0.41 | 0.88 | - | 0.09 | 0.19 | |
Revenue Growth (YoY) | -89.14% | -52.85% | - | - | -52.36% | - |
Cost of Revenue | 0.12 | 0.34 | 0.65 | - | 0.08 | 0.06 |
Gross Profit | 0.13 | 0.08 | 0.23 | - | 0.02 | 0.13 |
Selling, General & Admin | 2.68 | 3.39 | 3.24 | 4 | 5.08 | 5.61 |
Research & Development | 0.63 | 0.13 | 0.98 | 1.85 | 2.06 | - |
Other Operating Expenses | - | - | - | - | - | 0.82 |
Operating Expenses | 3.31 | 3.52 | 4.21 | 5.85 | 7.14 | 6.53 |
Operating Income | -3.19 | -3.44 | -3.99 | -5.85 | -7.12 | -6.4 |
Interest Expense | -0.04 | -0.03 | -0.05 | -0.03 | -0.03 | -0.11 |
Interest & Investment Income | - | - | - | 0.02 | - | - |
Earnings From Equity Investments | 0.44 | - | - | 0.02 | -0.06 | - |
Currency Exchange Gain (Loss) | 0.01 | 0.01 | -0.01 | -0.16 | 0.18 | - |
Other Non Operating Income (Expenses) | 0.09 | -0.01 | -0.16 | 0.01 | -0.34 | -0.08 |
EBT Excluding Unusual Items | -2.68 | -3.47 | -4.2 | -5.99 | -7.38 | -6.58 |
Impairment of Goodwill | - | - | - | - | -0.56 | - |
Other Unusual Items | - | - | - | - | - | -9.39 |
Pretax Income | 2.44 | -3.47 | -4.2 | -5.99 | -7.93 | -15.97 |
Earnings From Continuing Operations | 2.44 | -3.47 | -4.2 | -5.99 | -7.93 | -15.97 |
Minority Interest in Earnings | 0.4 | 0.19 | 0.32 | 0.4 | 0.21 | - |
Net Income | 2.84 | -3.28 | -3.88 | -5.59 | -7.73 | -15.97 |
Net Income to Common | 2.84 | -3.28 | -3.88 | -5.59 | -7.73 | -15.97 |
Shares Outstanding (Basic) | 18 | 33 | 29 | 28 | 26 | 11 |
Shares Outstanding (Diluted) | 18 | 33 | 29 | 28 | 26 | 11 |
Shares Change (YoY) | -57.55% | 12.68% | 4.79% | 6.98% | 127.75% | - |
EPS (Basic) | 0.16 | -0.10 | -0.13 | -0.20 | -0.30 | -1.40 |
EPS (Diluted) | 0.16 | -0.10 | -0.13 | -0.20 | -0.30 | -1.40 |
Free Cash Flow | -2.32 | -0.8 | -2.26 | -6.02 | -3.97 | -6.32 |
Free Cash Flow Per Share | -0.13 | -0.02 | -0.08 | -0.22 | -0.15 | -0.55 |
Gross Margin | 51.85% | 18.40% | 25.69% | - | 17.58% | 69.63% |
Operating Margin | -1310.70% | -832.69% | -455.14% | - | -7825.28% | -3348.69% |
Profit Margin | 1169.14% | -794.92% | -442.81% | - | -8492.31% | -8359.16% |
Free Cash Flow Margin | -954.73% | -192.49% | -258.22% | - | -4367.03% | -3309.42% |
EBITDA | -3.29 | -3.41 | -3.96 | -5.79 | -6.93 | -6.3 |
D&A For EBITDA | -0.11 | 0.03 | 0.03 | 0.06 | 0.19 | 0.1 |
EBIT | -3.19 | -3.44 | -3.99 | -5.85 | -7.12 | -6.4 |